Iovance Biotherapeutics Stock Price - IOVA

-0.06 (-0.21%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Iovance Biotherapeutics Inc IOVA NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.18 0.62% 29.06 27.50 29.25 28.68 28.88 00:00:07
Bid Price Ask Price Spread Spread % News
26.56 32.00 5.44 17.0% 1 -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
9,220 950,076 $ 28.36 $ 26,943,753 2,691,114 9.82 - 39.10
Last Trade Time Type Quantity Stock Price Currency
19:59:57 25 $ 29.00 USD

Iovance Biotherapeutics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 3.68B 126.50M $ -123.58M -1.59 - 105.72M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Iovance Biotherapeutics News

Loading Messages....

Latest IOVA Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical IOVA Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week30.8033.9927.0929.791,871,654-1.74-5.65%
1 Month35.7839.1018.7028.272,468,879-6.72-18.78%
3 Months27.8939.1018.7028.481,956,8861.174.2%
6 Months19.4339.1017.7826.451,542,4389.6349.56%
1 Year9.9639.109.8222.401,611,66319.10191.77%
3 Years7.5039.104.4516.801,117,77421.56287.47%
5 Years13.0639.104.2415.24815,86616.00122.51%

Iovance Biotherapeutics Description

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. It's lead pipeline candidate, LN-145, is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) to treat patients with refractory metastatic melanoma.

Your Recent History
Iovance Bi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.